世界のCD38モノクローナル抗体薬市場2021-2026:ダレツズマブ、イサルツキシマブ、人工毒素体

LP Informationが発行した調査報告書(LPI21MY9468)
◆英語タイトル:Global CD38 Monoclonal Antibody Drugs Market Growth 2021-2026
◆商品コード:LPI21MY9468
◆発行会社(リサーチ会社):LP Information
◆発行日:2021年5月(※2024年版があります。お問い合わせください)
◆ページ数:92
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2-3営業日)
◆調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はLP Information社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。LP Information社の概要及び新刊レポートはこちらでご確認いただけます。

LPインフォメーション社の「CD38モノクローナル抗体薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、ダレツズマブ、イサルツキシマブ、人工毒素体など、用途別には、多発性骨髄腫、びまん性大細胞型B細胞リンパ腫、その他などにセグメント区分してまとめました。CD38モノクローナル抗体薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。
・CD38モノクローナル抗体薬の世界市場概要(サマリー)
・CD38モノクローナル抗体薬の企業別販売量・売上
・CD38モノクローナル抗体薬の企業別市場シェア
・CD38モノクローナル抗体薬の世界市場規模 2016年-2021年:種類別(ダレツズマブ、イサルツキシマブ、人工毒素体)
・CD38モノクローナル抗体薬の世界市場規模 2016年-2021年:用途別(多発性骨髄腫、びまん性大細胞型B細胞リンパ腫、その他)
・CD38モノクローナル抗体薬の南北アメリカ市場規模(アメリカ、カナダ、メキシコなど)
・CD38モノクローナル抗体薬のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・CD38モノクローナル抗体薬のヨーロッパ市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・CD38モノクローナル抗体薬の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・CD38モノクローナル抗体薬市場の成長要因・課題・動向
・CD38モノクローナル抗体薬の世界市場予測 2021年-2026年
・CD38モノクローナル抗体薬の南北アメリカ市場予測(アメリカ、カナダ、メキシコなど)
・CD38モノクローナル抗体薬のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・CD38モノクローナル抗体薬のヨーロッパ市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・CD38モノクローナル抗体薬の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・CD38モノクローナル抗体薬の世界市場予測:種類別(ダレツズマブ、イサルツキシマブ、人工毒素体)
・CD38モノクローナル抗体薬の世界市場予測:用途別(多発性骨髄腫、びまん性大細胞型B細胞リンパ腫、その他)
・主要企業分析
【レポートの概要】

According to this latest study, the 2021 growth of CD38 Monoclonal Antibody Drugs will have significant change from previous year. By the most conservative estimates of global CD38 Monoclonal Antibody Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the CD38 Monoclonal Antibody Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of CD38 Monoclonal Antibody Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Daretuzumab
Isartuximab
Engineered Toxin Body

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Multiple Myeloma
Diffuse Large B Cell Lymphoma
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Johnson
Sanofi
Takeda Pharmaceutical Company
CASI Pharmaceutical Company
Mab Biopharma

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global CD38 Monoclonal Antibody Drugs Consumption 2016-2026
2.1.2 CD38 Monoclonal Antibody Drugs Consumption CAGR by Region
2.2 CD38 Monoclonal Antibody Drugs Segment by Type
2.2.1 Daretuzumab
2.2.2 Isartuximab
2.2.3 Engineered Toxin Body
2.3 CD38 Monoclonal Antibody Drugs Sales by Type
2.3.1 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2016-2021)
2.3.2 Global CD38 Monoclonal Antibody Drugs Revenue and Market Share by Type (2016-2021)
2.3.3 Global CD38 Monoclonal Antibody Drugs Sale Price by Type (2016-2021)
2.4 CD38 Monoclonal Antibody Drugs Segment by Application
2.4.1 Multiple Myeloma
2.4.2 Diffuse Large B Cell Lymphoma
2.4.3 Other
2.5 CD38 Monoclonal Antibody Drugs Sales by Application
2.5.1 Global CD38 Monoclonal Antibody Drugs Sale Market Share by Application (2016-2021)
2.5.2 Global CD38 Monoclonal Antibody Drugs Revenue and Market Share by Application (2016-2021)
2.5.3 Global CD38 Monoclonal Antibody Drugs Sale Price by Application (2016-2021)

3 Global CD38 Monoclonal Antibody Drugs by Company
3.1 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Company
3.1.1 Global CD38 Monoclonal Antibody Drugs Sales by Company (2019-2021)
3.1.2 Global CD38 Monoclonal Antibody Drugs Sales Market Share by Company (2019-2021)
3.2 Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company
3.2.1 Global CD38 Monoclonal Antibody Drugs Revenue by Company (2019-2021)
3.2.2 Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company (2019-2021)
3.3 Global CD38 Monoclonal Antibody Drugs Sale Price by Company
3.4 Global Manufacturers CD38 Monoclonal Antibody Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers CD38 Monoclonal Antibody Drugs Product Location Distribution
3.4.2 Players CD38 Monoclonal Antibody Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 CD38 Monoclonal Antibody Drugs by Region
4.1 Global CD38 Monoclonal Antibody Drugs by Region
4.1.1 Global CD38 Monoclonal Antibody Drugs Sales by Region
4.1.2 Global CD38 Monoclonal Antibody Drugs Revenue by Region
4.2 Americas CD38 Monoclonal Antibody Drugs Sales Growth
4.3 APAC CD38 Monoclonal Antibody Drugs Sales Growth
4.4 Europe CD38 Monoclonal Antibody Drugs Sales Growth
4.5 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Growth

5 Americas
5.1 Americas CD38 Monoclonal Antibody Drugs Sales by Country
5.1.1 Americas CD38 Monoclonal Antibody Drugs Sales by Country (2016-2021)
5.1.2 Americas CD38 Monoclonal Antibody Drugs Revenue by Country (2016-2021)
5.2 Americas CD38 Monoclonal Antibody Drugs Sales by Type
5.3 Americas CD38 Monoclonal Antibody Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC CD38 Monoclonal Antibody Drugs Sales by Region
6.1.1 APAC CD38 Monoclonal Antibody Drugs Sales by Region (2016-2021)
6.1.2 APAC CD38 Monoclonal Antibody Drugs Revenue by Region (2016-2021)
6.2 APAC CD38 Monoclonal Antibody Drugs Sales by Type
6.3 APAC CD38 Monoclonal Antibody Drugs Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe CD38 Monoclonal Antibody Drugs by Country
7.1.1 Europe CD38 Monoclonal Antibody Drugs Sales by Country (2016-2021)
7.1.2 Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2016-2021)
7.2 Europe CD38 Monoclonal Antibody Drugs Sales by Type
7.3 Europe CD38 Monoclonal Antibody Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa CD38 Monoclonal Antibody Drugs by Country
8.1.1 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Country (2016-2021)
8.1.2 Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Country (2016-2021)
8.2 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Type
8.3 Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 CD38 Monoclonal Antibody Drugs Distributors
10.3 CD38 Monoclonal Antibody Drugs Customer

11 Global CD38 Monoclonal Antibody Drugs Market Forecast
11.1 Global CD38 Monoclonal Antibody Drugs Forecast by Region
11.1.1 Global CD38 Monoclonal Antibody Drugs Forecast by Regions (2021-2026)
11.2.2 Global CD38 Monoclonal Antibody Drugs Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Country
11.3 APAC Forecast by Region
11.4 Europe Forecast by Country
11.5 Middle East & Africa Forecast by Country
11.6 Global CD38 Monoclonal Antibody Drugs Forecast by Type
11.7 Global CD38 Monoclonal Antibody Drugs Forecast by Application

12 Key Players Analysis
12.1 Johnson
12.1.1 Johnson Company Information
12.1.2 Johnson CD38 Monoclonal Antibody Drugs Product Offered
12.1.3 Johnson CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Johnson Main Business Overview
12.1.5 Johnson Latest Developments
12.2 Sanofi
12.2.1 Sanofi Company Information
12.2.2 Sanofi CD38 Monoclonal Antibody Drugs Product Offered
12.2.3 Sanofi CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Sanofi Main Business Overview
12.2.5 Sanofi Latest Developments
12.3 Takeda Pharmaceutical Company
12.3.1 Takeda Pharmaceutical Company Company Information
12.3.2 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Offered
12.3.3 Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Takeda Pharmaceutical Company Main Business Overview
12.3.5 Takeda Pharmaceutical Company Latest Developments
12.4 CASI Pharmaceutical Company
12.4.1 CASI Pharmaceutical Company Company Information
12.4.2 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Offered
12.4.3 CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 CASI Pharmaceutical Company Main Business Overview
12.4.5 CASI Pharmaceutical Company Latest Developments
12.5 Mab Biopharma
12.5.1 Mab Biopharma Company Information
12.5.2 Mab Biopharma CD38 Monoclonal Antibody Drugs Product Offered
12.5.3 Mab Biopharma CD38 Monoclonal Antibody Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Mab Biopharma Main Business Overview
12.5.5 Mab Biopharma Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. CD38 Monoclonal Antibody Drugs Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Daretuzumab
Table 3. Major Players of Isartuximab
Table 4. Major Players of Engineered Toxin Body
Table 5. Global CD38 Monoclonal Antibody Drugs Sales by Type (2016-2021) & (KG)
Table 6. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2016-2021)
Table 7. Global CD38 Monoclonal Antibody Drugs Revenue by Type (2016-2021) & ($ million)
Table 8. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2016-2021)
Table 9. Global CD38 Monoclonal Antibody Drugs Sale Price by Type (2016-2021)
Table 10. Global CD38 Monoclonal Antibody Drugs Sales by Application (2016-2021) & (KG)
Table 11. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2016-2021)
Table 12. Global CD38 Monoclonal Antibody Drugs Value by Application (2016-2021)
Table 13. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application (2016-2021)
Table 14. Global CD38 Monoclonal Antibody Drugs Sale Price by Application (2016-2021)
Table 15. Global CD38 Monoclonal Antibody Drugs Sales by Company (2019-2021) & (KG)
Table 16. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Company (2019-2021)
Table 17. Global CD38 Monoclonal Antibody Drugs Revenue by Company (2019-2021) ($ Millions)
Table 18. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company (2019-2021)
Table 19. Global CD38 Monoclonal Antibody Drugs Sale Price by Company (2019-2021)
Table 20. Key Manufacturers CD38 Monoclonal Antibody Drugs Producing Area Distribution and Sales Area
Table 21. Players CD38 Monoclonal Antibody Drugs Products Offered
Table 22. CD38 Monoclonal Antibody Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global CD38 Monoclonal Antibody Drugs Sales by Region (2016-2021) (KG)
Table 26. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2016-2021)
Table 27. Global CD38 Monoclonal Antibody Drugs Revenue by Region (2016-2021) & ($ Millions)
Table 28. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Region (2016-2021)
Table 29. Americas CD38 Monoclonal Antibody Drugs Sales by Country (2016-2021) & (KG)
Table 30. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2016-2021)
Table 31. Americas CD38 Monoclonal Antibody Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 32. Americas CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2016-2021)
Table 33. Americas CD38 Monoclonal Antibody Drugs Sales by Type (2016-2021) & (KG)
Table 34. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2016-2021)
Table 35. Americas CD38 Monoclonal Antibody Drugs Sales by Application (2016-2021) & (KG)
Table 36. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2016-2021)
Table 37. APAC CD38 Monoclonal Antibody Drugs Sales by Region (2016-2021) & (KG)
Table 38. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Region (2016-2021)
Table 39. APAC CD38 Monoclonal Antibody Drugs Revenue by Region (2016-2021) & ($ Millions)
Table 40. APAC CD38 Monoclonal Antibody Drugs Revenue Market Share by Region (2016-2021)
Table 41. APAC CD38 Monoclonal Antibody Drugs Sales by Type (2016-2021) & (KG)
Table 42. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2016-2021)
Table 43. APAC CD38 Monoclonal Antibody Drugs Sales by Application (2016-2021) & (KG)
Table 44. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2016-2021)
Table 45. Europe CD38 Monoclonal Antibody Drugs Sales by Country (2016-2021) & (KG)
Table 46. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2016-2021)
Table 47. Europe CD38 Monoclonal Antibody Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 48. Europe CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2016-2021)
Table 49. Europe CD38 Monoclonal Antibody Drugs Sales by Type (2016-2021) & (KG)
Table 50. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2016-2021)
Table 51. Europe CD38 Monoclonal Antibody Drugs Sales by Application (2016-2021) & (KG)
Table 52. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2016-2021)
Table 53. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Country (2016-2021) & (KG)
Table 54. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Country (2016-2021)
Table 55. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 56. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Market Share by Country (2016-2021)
Table 57. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Type (2016-2021) & (KG)
Table 58. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Type (2016-2021)
Table 59. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales by Application (2016-2021) & (KG)
Table 60. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2016-2021)
Table 61. Key and Potential Regions of CD38 Monoclonal Antibody Drugs
Table 62. Key Application and Potential Industries of CD38 Monoclonal Antibody Drugs
Table 63. Key Challenges of CD38 Monoclonal Antibody Drugs
Table 64. Key Trends of CD38 Monoclonal Antibody Drugs
Table 65. CD38 Monoclonal Antibody Drugs Distributors List
Table 66. CD38 Monoclonal Antibody Drugs Customer List
Table 67. Global CD38 Monoclonal Antibody Drugs Sales Forecast by Region (2021-2026) & (KG)
Table 68. Global CD38 Monoclonal Antibody Drugs Consumption Market Forecast by Region
Table 69. Global CD38 Monoclonal Antibody Drugs Revenue Forecast by Region (2021-2026) & ($ millions)
Table 70. Global CD38 Monoclonal Antibody Drugs Revenue Market Share Forecast by Region (2021-2026)
Table 71. Americas CD38 Monoclonal Antibody Drugs Sales Forecast by Country (2021-2026) & (KG)
Table 72. Americas CD38 Monoclonal Antibody Drugs Revenue Forecast by Country (2021-2026) & ($ millions)
Table 73. APAC CD38 Monoclonal Antibody Drugs Sales Forecast by Region (2021-2026) & (KG)
Table 74. APAC CD38 Monoclonal Antibody Drugs Revenue Forecast by Region (2021-2026) & ($ millions)
Table 75. Europe CD38 Monoclonal Antibody Drugs Sales Forecast by Country (2021-2026) & (KG)
Table 76. Europe CD38 Monoclonal Antibody Drugs Revenue Forecast by Country (2021-2026) & ($ millions)
Table 77. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Forecast by Country (2021-2026) & (KG)
Table 78. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Forecast by Country (2021-2026) & ($ millions)
Table 79. Global CD38 Monoclonal Antibody Drugs Sales Forecast by Type (2021-2026) & (KG)
Table 80. Global CD38 Monoclonal Antibody Drugs Sales Market Share Forecast by Type (2021-2026)
Table 81. Global CD38 Monoclonal Antibody Drugs Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 82. Global CD38 Monoclonal Antibody Drugs Revenue Market Share Forecast by Type (2021-2026)
Table 83. Global CD38 Monoclonal Antibody Drugs Sales Forecast by Application (2021-2026) & (KG)
Table 84. Global CD38 Monoclonal Antibody Drugs Sales Market Share Forecast by Application (2021-2026)
Table 85. Global CD38 Monoclonal Antibody Drugs Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 86. Global CD38 Monoclonal Antibody Drugs Revenue Market Share Forecast by Application (2021-2026)
Table 87. Johnson Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Johnson CD38 Monoclonal Antibody Drugs Product Offered
Table 89. Johnson CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2021E)
Table 90. Johnson Main Business
Table 91. Johnson Latest Developments
Table 92. Sanofi Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Sanofi CD38 Monoclonal Antibody Drugs Product Offered
Table 94. Sanofi CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2021E)
Table 95. Sanofi Main Business
Table 96. Sanofi Latest Developments
Table 97. Takeda Pharmaceutical Company Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Offered
Table 99. Takeda Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2021E)
Table 100. Takeda Pharmaceutical Company Main Business
Table 101. Takeda Pharmaceutical Company Latest Developments
Table 102. CASI Pharmaceutical Company Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Product Offered
Table 104. CASI Pharmaceutical Company CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2021E)
Table 105. CASI Pharmaceutical Company Main Business
Table 106. CASI Pharmaceutical Company Latest Developments
Table 107. Mab Biopharma Basic Information, CD38 Monoclonal Antibody Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Mab Biopharma CD38 Monoclonal Antibody Drugs Product Offered
Table 109. Mab Biopharma CD38 Monoclonal Antibody Drugs Sales (KG), Revenue ($ Million), Price (US$/g) and Gross Margin (2019-2021E)
Table 110. Mab Biopharma Main Business
Table 111. Mab Biopharma Latest Developments
List of Figures
Figure 1. Picture of CD38 Monoclonal Antibody Drugs
Figure 2. CD38 Monoclonal Antibody Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global CD38 Monoclonal Antibody Drugs Sales Growth Rate 2016-2026 (KG)
Figure 7. Global CD38 Monoclonal Antibody Drugs Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. CD38 Monoclonal Antibody Drugs Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Daretuzumab
Figure 10. Product Picture of Isartuximab
Figure 11. Product Picture of Engineered Toxin Body
Figure 12. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Type in 2020
Figure 13. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Type (2016-2021)
Figure 14. CD38 Monoclonal Antibody Drugs Consumed in Multiple Myeloma
Figure 15. Global CD38 Monoclonal Antibody Drugs Market: Multiple Myeloma (2016-2021) & (KG)
Figure 16. CD38 Monoclonal Antibody Drugs Consumed in Diffuse Large B Cell Lymphoma
Figure 17. Global CD38 Monoclonal Antibody Drugs Market: Diffuse Large B Cell Lymphoma (2016-2021) & (KG)
Figure 18. CD38 Monoclonal Antibody Drugs Consumed in Other
Figure 19. Global CD38 Monoclonal Antibody Drugs Market: Other (2016-2021) & (KG)
Figure 20. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Application (2016-2021)
Figure 21. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Application in 2020
Figure 22. CD38 Monoclonal Antibody Drugs Revenue Market by Company in 2020 ($ Million)
Figure 23. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Company in 2020
Figure 24. Global CD38 Monoclonal Antibody Drugs Sales Market Share by Regions (2016-2021)
Figure 25. Global CD38 Monoclonal Antibody Drugs Revenue Market Share by Region in 2020
Figure 26. Americas CD38 Monoclonal Antibody Drugs Sales 2016-2021 (KG)
Figure 27. Americas CD38 Monoclonal Antibody Drugs Revenue 2016-2021 ($ Millions)
Figure 28. APAC CD38 Monoclonal Antibody Drugs Sales 2016-2021 (KG)
Figure 29. APAC CD38 Monoclonal Antibody Drugs Revenue 2016-2021 ($ Millions)
Figure 30. Europe CD38 Monoclonal Antibody Drugs Sales 2016-2021 (KG)
Figure 31. Europe CD38 Monoclonal Antibody Drugs Revenue 2016-2021 ($ Millions)
Figure 32. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales 2016-2021 (KG)
Figure 33. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue 2016-2021 ($ Millions)
Figure 34. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Country in 2020
Figure 35. Americas CD38 Monoclonal Antibody Drugs Revenue Market Share by Country in 2020
Figure 36. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Type in 2020
Figure 37. Americas CD38 Monoclonal Antibody Drugs Sales Market Share by Application in 2020
Figure 38. United States CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 39. Canada CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 40. Mexico CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 41. Brazil CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 42. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Region in 2020
Figure 43. APAC CD38 Monoclonal Antibody Drugs Revenue Market Share by Regions in 2020
Figure 44. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Type in 2020
Figure 45. APAC CD38 Monoclonal Antibody Drugs Sales Market Share by Application in 2020
Figure 46. China CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 47. Japan CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 48. Korea CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 49. Southeast Asia CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 50. India CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 51. Australia CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 52. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Country in 2020
Figure 53. Europe CD38 Monoclonal Antibody Drugs Revenue Market Share by Country in 2020
Figure 54. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Type in 2020
Figure 55. Europe CD38 Monoclonal Antibody Drugs Sales Market Share by Application in 2020
Figure 56. Germany CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 57. France CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 58. UK CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 59. Italy CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 60. Russia CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 61. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Country in 2020
Figure 62. Middle East & Africa CD38 Monoclonal Antibody Drugs Revenue Market Share by Country in 2020
Figure 63. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Type in 2020
Figure 64. Middle East & Africa CD38 Monoclonal Antibody Drugs Sales Market Share by Application in 2020
Figure 65. Egypt CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 66. South Africa CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 67. Israel CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 68. Turkey CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 69. GCC Country CD38 Monoclonal Antibody Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 70. Channels of Distribution
Figure 71. Distributors Profiles


【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のCD38モノクローナル抗体薬市場2021-2026:ダレツズマブ、イサルツキシマブ、人工毒素体(Global CD38 Monoclonal Antibody Drugs Market Growth 2021-2026)]についてメールでお問い合わせはこちらでお願いします。